MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 463268 | Name: 7-Oxo-staurosporine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

7-Oxo-staurosporine is a potent dual PKCθ/δ inhibitor, efficiently inhibiting tumor growth in pancreatic cancer (PC) by inducing cellular apoptosis and suppressing the NF-κB/p-P65 pathway.

Chemical Structure

7-Oxo-staurosporine
7-Oxo-staurosporine
CAS#141196-69-2

Theoretical Analysis

MedKoo Cat#: 463268

Name: 7-Oxo-staurosporine

CAS#: 141196-69-2

Chemical Formula: C28H24N4O4

Exact Mass: 480.1798

Molecular Weight: 480.52

Elemental Analysis: C, 69.99; H, 5.03; N, 11.66; O, 13.32

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
7-Oxo-staurosporine; 7 Oxo-staurosporine; 7-Oxostaurosporine; 7-Oxo staurosporine;
IUPAC/Chemical Name
(5S,6R,7R,9R)-6-methoxy-5-methyl-7-(methylamino)-6,7,8,9-tetrahydro-5H,14H-17-oxa-4b,9a,15-triaza-5,9-methanodibenzo[b,h]cyclonona[jkl]cyclopenta[e]-as-indacene-14,16(15H)-dione
InChi Key
POTTVLREWUNNRO-UGZRAAABSA-N
InChi Code
InChI=1S/C28H24N4O4/c1-28-25(35-3)15(29-2)12-18(36-28)31-16-10-6-4-8-13(16)19-21-22(27(34)30-26(21)33)20-14-9-5-7-11-17(14)32(28)24(20)23(19)31/h4-11,15,18,25,29H,12H2,1-3H3,(H,30,33,34)/t15-,18-,25-,28+/m1/s1
SMILES Code
O=C1NC(C(C2=C3N([C@]4(C)[C@H](OC)[C@H](NC)C[C@@]5([H])O4)C6=CC=CC=C62)=C1C7=C3N5C8=CC=CC=C78)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 480.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Wang J, Jin W, Zhou X, Li J, Xu C, Ma Z, Wang J, Qin L, Zhou B, Ding W, Gao T, Yao H, Chen Z. Identification, Structure-Activity Relationships of Marine- Derived Indolocarbazoles, and a Dual PKCθ/δ Inhibitor with Potent Antipancreatic Cancer Efficacy. J Med Chem. 2020 Oct 25. doi: 10.1021/acs.jmedchem.0c01271. Epub ahead of print. PMID: 33100009. 2: Rizo-Liendo A, Sifaoui I, Cartuche L, Arberas-Jiménez I, Reyes-Batlle M, Fernández JJ, Piñero JE, Díaz-Marrero AR, Lorenzo-Morales J. Evaluation of Indolocarbazoles from Streptomyces sanyensis as a Novel Source of Therapeutic Agents against the Brain-Eating Amoeba Naegleria fowleri. Microorganisms. 2020 May 25;8(5):789. doi: 10.3390/microorganisms8050789. PMID: 32466301; PMCID: PMC7285321. 3: Cartuche L, Sifaoui I, López-Arencibia A, Bethencourt-Estrella CJ, San Nicolás-Hernández D, Lorenzo-Morales J, Piñero JE, Díaz-Marrero AR, Fernández JJ. Antikinetoplastid Activity of Indolocarbazoles from Streptomyces sanyensis. Biomolecules. 2020 Apr 24;10(4):657. doi: 10.3390/biom10040657. PMID: 32344693; PMCID: PMC7226613. 4: Cartuche L, Reyes-Batlle M, Sifaoui I, Arberas-Jiménez I, Piñero JE, Fernández JJ, Lorenzo-Morales J, Díaz-Marrero AR. Antiamoebic Activities of Indolocarbazole Metabolites Isolated from Streptomyces sanyensis Cultures. Mar Drugs. 2019 Oct 17;17(10):588. doi: 10.3390/md17100588. PMID: 31627366; PMCID: PMC6836125. 5: Cho KJ, Park JH, Hancock JF. Staurosporine: A new tool for studying phosphatidylserine trafficking. Commun Integr Biol. 2013 Jul 1;6(4):e24746. doi: 10.4161/cib.24746. Epub 2013 May 10. PMID: 23986809; PMCID: PMC3737755. 6: Jimenez PC, Wilke DV, Ferreira EG, Takeara R, de Moraes MO, da Silveira ER, da Cruz Lotufo TM, Lopes NP, Costa-Lotufo LV. Structure elucidation and anticancer activity of 7-oxostaurosporine derivatives from the Brazilian endemic tunicate Eudistoma vannamei. Mar Drugs. 2012 May;10(5):1092-102. doi: 10.3390/md10051092. Epub 2012 May 21. PMID: 22822359; PMCID: PMC3397465. 7: Nomura M, Yamamoto H, Sugiura N, Miyamoto K. Leukocyte function-associated antigen 1-dependent adhesion of rat hepatoma AH66F cells and inhibition by protein kinase C inhibitors. Biochem Pharmacol. 1997 May 9;53(9):1333-7. doi: 10.1016/s0006-2952(96)00812-x. PMID: 9214694. 8: Osada H, Cui CB, Onose R, Hanaoka F. Screening of cell cycle inhibitors from microbial metabolites by a bioassay using a mouse cdc2 mutant cell line, tsFT210. Bioorg Med Chem. 1997 Jan;5(1):193-203. doi: 10.1016/s0968-0896(96)00207-6. PMID: 9043671. 9: Miyamoto K, Takeda K, Koga K, Ohshima T, Wakusawa S. Antitumour effects and pharmacokinetics of combination of vinblastine with a staurosporine derivative, NA-382, in P388/ADR-bearing mice. J Pharm Pharmacol. 1995 Jun;47(6):524-9. doi: 10.1111/j.2042-7158.1995.tb05843.x. PMID: 7674138. 10: Miyamoto K, Inoko K, Wakusawa S, Kajita S, Hasegawa T, Takagi K, Koyama M. Inhibition of multidrug resistance by a new staurosporine derivative, NA-382, in vitro and in vivo. Cancer Res. 1993 Apr 1;53(7):1555-9. PMID: 8095855. 11: Miyamoto K, Inoko K, Ikeda K, Wakusawa S, Kajita S, Hasegawa T, Takagi K, Koyama M. Effect of staurosporine derivatives on protein kinase activity and vinblastine accumulation in mouse leukaemia P388/ADR cells. J Pharm Pharmacol. 1993 Jan;45(1):43-7. doi: 10.1111/j.2042-7158.1993.tb03677.x. PMID: 8094445. 12: Miyamoto K, Wakusawa S, Inoko K, Takagi K, Koyama M. Reversal of vinblastine resistance by a new staurosporine derivative, NA-382, in P388/ADR cells. Cancer Lett. 1992 Jun 15;64(2):177-83. doi: 10.1016/0304-3835(92)90079-b. PMID: 1351792. 13: Koshino H, Osada H, Isono K. A new inhibitor of protein kinase C, RK-1409 (7-oxostaurosporine). II. Fermentation, isolation, physico-chemical properties and structure. J Antibiot (Tokyo). 1992 Feb;45(2):195-8. doi: 10.7164/antibiotics.45.195. PMID: 1556010. 14: Osada H, Koshino H, Kudo T, Onose R, Isono K. A new inhibitor of protein kinase C, RK-1409 (7-oxostaurosporine). I. Taxonomy and biological activity. J Antibiot (Tokyo). 1992 Feb;45(2):189-94. doi: 10.7164/antibiotics.45.189. PMID: 1556009.

View History

LON65724

LON65724

Featured